The effects of pergolide on memory and oxidative stress in a rat model of Parkinson's disease

Journal of Physiology and Biochemistry

Volumn 68, Issue 1, 2012, Pages 59-69

  Ciobica, Alin ^a   Olteanu, Zenovia ^a   Padurariu, Manuela ^b   Hritcu, Lucian ^a  

^a ALEXANDRU IOAN CUZA UNIVERSITY OF IASI   (Romania)

^b GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

6 Hydroxydopamine; Animal model; Oxidative stress; Parkinson's disease; Pergolide

Indexed keywords

GLUTATHIONE PEROXIDASE; MALONALDEHYDE; OXIDOPAMINE; PERGOLIDE; SUPEROXIDE DISMUTASE;

AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; LIPID PEROXIDATION; LOW DRUG DOSE; MALE; MEMORY; NEUROSURGERY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; RAT; REFERENCE MEMORY; SPATIAL MEMORY; SUBSTANTIA NIGRA PARS COMPACTA; TEMPORAL LOBE; WORKING MEMORY;

ANIMALS; DISEASE MODELS, ANIMAL; DOPAMINE AGONISTS; GLUTATHIONE PEROXIDASE; LINEAR MODELS; LIPID PEROXIDATION; MALE; MALONDIALDEHYDE; MAZE LEARNING; MEMORY; OXIDATIVE STRESS; OXIDOPAMINE; PARKINSONIAN DISORDERS; PERGOLIDE; RATS; RATS, WISTAR; SUPEROXIDE DISMUTASE; TEMPORAL LOBE;

ANIMALIA; RATTUS;

EID: 84858058939     PISSN: 11387548     EISSN: 18778755     Source Type: Journal    
DOI: 10.1007/s13105-011-0119-x     Document Type: Article

References (57)

1. Abeliovich A (2010) Parkinson's disease: mitochondrial damage control. Nature 463:744-745
2. Avila I, Reilly MP, Sanabria F, Posadas-Sánchez D, Chavez CL, Banerjee N, Killeen P, Castañeda E (2009) Modeling operant behavior in the parkinsonian rat. Behav Brain Res 198:298-305
3. Berretta N, Freestone PS, Guatteo E, de Castro D, Geracitano R, Bernardi G, Mercuri NB, Lipski J (2005) Acute effects of 6-hydroxydopamine on dopaminergic neurons of the rat substantia nigra pars compacta in vitro. Neurotoxicology 26:869-881 (Pubitemid 41427527)
4. Bisaglia M, Soriano ME, Arduini I, Mammi S, Bubacco L (2010) Molecular characterization of dopamine-derived quinones reactivity toward NADH and glutathione: implications for mitochondrial dysfunction in Parkinson disease. Biochim Biophys Acta. doi:10.1016/j.bbadis.2010.06.006
5. Blandini F, Levandis G, Bazzini E, Nappi G, Armentero MT (2007) Time-course of nigrostriatal damage, basal ganglia metabolic changes and behavioural alterations following intrastriatal injection of 6-hydroxydopamine in the rat: new clues from an old model. Eur J Neurosci 25:397-405
6. Branchi I, D'Andrea I, Armida M, Carnevale D, Ajmone-Cat MA, Pèzzola A, Potenza RL, Morgese MG, Cassano T, Minghetti L, Popoli P, Alleva E (2010) Striatal 6-OHDA lesion in mice: investigating early neurochemical changes underlying Parkinson's disease. Behav Brain Res 208:137-143
7. Brusa L, Tiraboschi P, Koch G, Peppe A, Pierantozzi M, Ruggieri S, Stanzione P (2005) Pergolide effect on cognitive functions in early-mild Parkinson's disease. J Neural Transm 112:231-237 (Pubitemid 40185372)
8. Chalimoniuk M, Stepień A, Strosznajder JB (2004) Pergolide mesylate, a dopaminergic receptor agonist, applied with L-DOPA enhances serum antioxidant enzyme activity in Parkinson disease. Clin Neuropharmacol 27:223-229 (Pubitemid 39447219)
9. Ciobica A, Hritcu L, Artenie V (2009) Changes in the activity of the antioxidant enzymes in 6-hydroxydopamineinduced rat model of Parkinson's disease. J Neurol Sci 283:282-283
10. Ciobica A, Hritcu L, Artenie V, PadurariuM(2008) Cognitive disorders in a 6-hydroxydopamine-induced rat model of Parkinson's disease. Eur Neuropsychopharmacol 18:276
11. Ciobica A, Hritcu L, Artenie V, Padurariu M (2008) Some aspects of oxidative stress in a rat model of of Parkinson's disease. Int J Neuropsychopharmacol 11:228-229
12. Ciobica A, Hritcu L, Artenie V, Padurariu M (2008) The effects of 6-OHDA in the rat brain (memory and oxidative stress processes). Proceedings of the 16th European . Congress of Physical and Rehabilitation Medicine, Brugge, Belgium, 3-6 June 2008. Edizioni Minerva Medica, Turin, pp 132-135
13. Ciobica A, Hritcu L, Artenie V, Padurariu M, Bild W (2009) A possible correlation between memory and neuronal oxidative stress status in a 6-OHDA model of Parkinson's disease. Parkinsonism Relat Disord 15:177-178
14. Ciobica A, Hritcu L, Artenie V, Stoica B, Bild V (2009) Effects of 6-OHDA infusion into the hypothalamic paraventricular nucleus in mediating stress-induced behavioural responses and oxidative damage in rats. Acta Endocrinol 5:425-436
15. Ciobica A, Hritcu L, Padurariu M, Dobrin R, Bild V (2010) Effects of serotonin depletion on behavior and neuronal oxidative stress status in rat: relevance for anxiety and affective disorders. Adv Med Sci 55(2):89-296
16. Costa A, Peppe A, Dell'Agnello G, Caltagirone C, Carlesimo GA (2009) Dopamine and cognitive functioning in de novo subjects with Parkinson's disease: effects of pramipexole and pergolide on working memory. Neuropsychologia 47:1374-1381
17. da Conceição FS, Ngo-Abdalla S, Houzel JC, Rehen SK (2010) Murine model for Parkinson's disease: from 6-OH dopamine lesion to behavioral test. J Vis Exp 35. doi:10.3791/1376
18. De Leonibus E, Managò F, Giordani F, Petrosino F, Lopez S, Oliverio A, Amalric M, Mele A (2009) Metabotropic glutamate receptors 5 blockade reverses spatial memory deficits in a mouse model of Parkinson's disease. Neuropsychopharmacology 34:729-738
19. De Leonibus E, Pascucci T, Lopez S, Oliverio A, Amalric M, Mele A (2007) Spatial deficits in a mouse model of Parkinson disease. Psychopharmacology (Berl) 194:517-525 (Pubitemid 47492993)
20. Ferro MM, Bellissimo MI, Anselmo-Franci JA, Angellucci ME, Canteras NS, Da Cunha C (2005) Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of the early phase of Parkinson's disease: histological, neurochemical, motor and memory alterations. J Neurosci Methods 148:78-87 (Pubitemid 41423461)
21. Forster MJ, Dubey A, Dawson KM, Stutts WA, Lal H, Sohal RS (1996) Age-related losses of cognitive function and motor skills in mice are associated with oxidative protein damage in the brain. Proc Natl Acad Sci USA 93:4765-4769 (Pubitemid 26162825)
22. Friedman A, Galazka-Friedman J, Koziorowski D (2009) Iron as a cause of Parkinson disease - a myth or a well established hypothesis? Parkinsonism Relat Disord 15:212-214
23. Gille G, Rausch WD, Hung ST, Moldzio R, Janetzky B, Hundemer HP, Kolter T, Reichmann H (2002) Pergolide protects dopaminergic neurons in primary culture under stress conditions. J Neural Transm 109:633-643 (Pubitemid 34810761)
24. Gomez-Vargas M, Nishibayashi-Asanuma S, Asanuma M (1998) Pergolide scavenges both hydroxyl and nitric oxide free radicals in vitro and inhibits peroxidation in different regions of the rat brain. Brain Res 790:202-208 (Pubitemid 28234504)
25. Gurzu C, Artenie V, Hritcu L, Ciobica A (2008) Prenatal testosterone improves the spatial learning and memory by protein synthesis in different lobes of the brain in the male and female rat. Cent Eur J Biol 3:39-47 (Pubitemid 351659768)
26. Halliwell B, Gutteridge JMC (2007) Free radical in biology and medicine, 4th edn. Oxford Univ Press, New York
27. Hanrott K, Gudmunsen L, O'Neill MJ, Wonnacott S (2006) 6-Hydroxydopamine-induced apoptosis is mediated via extracellular autooxidation and caspase 3-dependent activation of protein kinase C delta. J Biol Chem 281:5373-5382 (Pubitemid 43847631)
28. Hritcu L, Ciobica A, Artenie V (2008) Effects of right-unilateral 6-hydroxydopamine infusion-induced memory impairment and oxidative stress: relevance for Parkinson's disease. Cent Eur J Biol 3:250-257
29. Hritcu L, Ciobica A, Gorgan L (2009) Nicotine-induced memory impairment by increasing brain oxidative stress. Cent Eur J Biol 4:335-342
30. Iancu R, Mohapel P, Brundin P, Paul G (2005) Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice. Behav Brain Res 162:1-10 (Pubitemid 40726275)
31. Karelson E, Bogdanovic N, Garlind A, Winblad B, Zilmer K, Kullisaar T, Vihalemm T, Kairane C, Zilmer M (2001) The cerebrocortical areas in normal brain aging and in Alzheimer's disease: noticeable differences in the lipid peroxidation level and in antioxidant defense. Neurochem Res 26:353-361 (Pubitemid 32685953)
32. Kimberg DY, D'Esposito M (2003) Cognitive effects of the dopamine receptor agonist pergolide. Neuropsychologia 41:1020-1027 (Pubitemid 36349393)
33. Küçükatay V, Balkan S, Yaraş N, Yargiçoǧlu P, Aǧar A (2002) The effect of pergolide on cognitive performance of young and middle-aged rats. Int J Neurosci 112:1027-1036
34. Le WD, Jankovic J (2001) Are dopamine receptor agonists neuroprotective in Parkinson's disease? Drugs Aging 18:389-396
35. Levin ED (1995) Pergolide interactions with nicotine and pilocarpine in rats on the radial-arm maze. Pharmacol Biochem Behav 52:837-840
36. Mehta MA, Riedel WJ (2006) Dopaminergic enhancement of cognitive function. Curr Pharm Des 12:2487-2500
37. Mei J, Niu C (2010) Alterations of Hrd1 expression in various encephalic regional neurons in 6-OHDA model of Parkinson's disease. Neurosci Lett 474:63-68
38. Micale V, Incognito T, Ignoto A, Rampello L, Spartà M, Drago F (2006) Dopaminergic drugs may counteract behavioral and biochemical changes induced by models of brain injury. Eur Neuropsychopharmacol 16:195-203
39. Navarro A, Sánchez Del Pino MJ, Gómez C, Peralta JL, Boveris A (2002) Behavioral dysfunction, brain oxidative stress, and impaired mitochondrial electron transfer in aging mice. Am J Physiol Regul Integr Comp Physiol 282:985-992
40. Ono S, Hirai K, Tokuda E (2009) Effects of pergolide mesilate on metallothionein mRNAs expression in a mouse model for Parkinson disease. Biol Pharm Bull 32:1813-1817
41. Opacka-Juffry J, Wilson AW, Blunt SB (1998) Effects of pergolide treatment on in vivo hydroxyl free radical formation during infusion of 6-hydroxyldopamine in rat striatum. Brain Res 810:27-33 (Pubitemid 29003386)
42. Ozer F, Tiras R, Cetin S, Ozturk O, Aydemir T, Ozben S, Meral H, Kizkin S, Bader H, Ozben B (2009) Valvular heart disease in patients with Parkinson's disease treated with pergolide, levodopa or both. J Clin Neurosci 16:83-87
43. Padurariu M, Ciobica A, Dobrin I, Stefanescu C (2010) Evaluation of antioxidant enzymes activities and lipid peroxidation in schizophrenic patients treated with typical and atypical antipsychotics. Neurosci Lett 479:317-320
44. Padurariu M, Ciobica A, Hritcu L, Stoica B, Bild W, Stefanescu C (2010) Changes of some oxidative stress markers in the serum of patients with mild cognitiveimpairment and Alzheimer's disease. Neurosci Lett 469:6-10
45. Paxinos G, Watson C (2006) The rat brain in stereotaxic coordinates, 6th edn. Academic, San Diego
46. Possin KL, Filoteo JV, Song DD, Salmon DP (2008) Spatial and object working memory deficits in Parkinson's disease are due to impairment in different underlying processes. Neuropsychology 22:585-595
47. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E (2007) Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 356:29-38 (Pubitemid 46041751)
48. Schapira AH, Tolosa E (2010) Molecular and clinical prodrome of Parkinson disease: implications for treatment. Nat Rev Neurol 6:309-317
49. Seet RC, Lee CY, Lim EC, Tan JJ, Quek AM, Chong WL, Looi WF, Huang SH, Wang H, Chan YH, Halliwell B (2010) Oxidative damage in Parkinson disease: measurement using accurate biomarkers. Free Radic Biol Med 48:560-566
50. Shukitt-Hale B (1999) The effects of aging and oxidative stress on psychomotor and cognitive behavior. Age 22:9-17
51. Shukitt-Hale B, Denisova NA, Strain JG, Joseph JA (1997) Psychomotor effects of dopamine infusion under decreased glutathione conditions. Free Radic Biol Med 23:412-418 (Pubitemid 27276777)
52. Shukitt-Hale B, Erat SA, Joseph JA (1998) Spatial learning and memory deficits induced by dopamine administration with decreased glutathione. Free Radic Biol Med 24:1149-1158 (Pubitemid 28246728)
53. Spencer Smith T, Parker W, Bennett J (1994) Levodopa increases nigral production of hydroxyl radicals in vivo: potential levodopa toxicity? Neuroreport 5:1009-10011
54. Uberti D, Carsana T, Francisconi S, Ferrari Toninelli G, Canonico PL, Memo M (2004) A novel mechanism for pergolide-induced neuroprotection: inhibition of NF-kappaB nuclear translocation. Biochem Pharmacol 67:1743-1750 (Pubitemid 38479852)
55. Uberti D, Piccioni L, Colzi A, Bravi D, Canonico PL, Memo M (2002) Pergolide protects SH-SY5Y cells against neurodegeneration induced by H(2)O(2). Eur J Pharmacol 434:17-20 (Pubitemid 34033740)
56. Van Camp G, Flamez A, Cosyns B,Weytjens C, Muyldermans L, Van Zandijcke M, De Sutter J, Santens P, Decoodt P, Moerman C, Schoors D (2004) Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 363:1179-1183 (Pubitemid 38481842)
57. Wypijewska A, Galazka-Friedman J, Bauminger ER, Wszolek ZK, Schweitzer KJ, Dickson DW, Jaklewicz A, Elbaum D, Friedman A (2010) Iron and reactive oxygen species activity in parkinsonian substantia nigra. Parkinsonism Relat Disord 16:329-333